Koselugo approved in the EU for children with neurofibromatosis type 1 and plexiform neurofibromas
First medicine approved in the EU to treat this rare and debilitating genetic condition SPRINT Phase II trial showed Koselugo reduced tumour volume, reducing pain and improving quality of lifeAstraZeneca and MSD's Koselugo (selumetinib) has been granted conditional approval in the European Union (EU) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged three years and above. NF1 is a debilitating genetic condition affecting one in 3,000 individuals worldwide.[1,2] In 30-50% of people with NF1, tumours